Clinacanthus nutans (Burm.f.) Lindau facilitates cuproptosis and ameliorates colon cancer progression by inhibiting PDE3B-mediated Apelin pathway

Background Colon cancer, a prevalent malignancy occurs in the gastrointestinal tract with annually increasing incidence and mortality, and Clinacanthus nutans (Burm.f.) Lindau (CN) possesses anticancer activity in a wide spectrum of tumors. This investigation aims at illuminating potential anti-canc...

Full description

Saved in:
Bibliographic Details
Published inDiscover. Oncology Vol. 16; no. 1; pp. 1521 - 15
Main Authors Zhou, Gaoyun, Lin, Xueying, Lai, Zhiheng, Su, Dewen, Lin, Long, Chen, Xuewu
Format Journal Article
LanguageEnglish
Published New York Springer US 11.08.2025
Springer Nature B.V
Springer
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background Colon cancer, a prevalent malignancy occurs in the gastrointestinal tract with annually increasing incidence and mortality, and Clinacanthus nutans (Burm.f.) Lindau (CN) possesses anticancer activity in a wide spectrum of tumors. This investigation aims at illuminating potential anti-cancer properties and related mechanisms of CN against colon cancer. Methods A BALB/c mice model of colon cancer administered CN to the experimental group was constructed, followed by transcriptome sequencing on tumor tissues and screening out cuproptosis-related differentially expressed genes (DEGs) through bioinformatics. The anti-tumor efficacy of CN was validated in HT29 and HCT116 cells co-treatment of CN and drug serum by functional assays and therapeutic effects on tumorigenicity were also evaluated in vivo. In addition, the impact of PDE3B silencing on cuproptosis was elucidated and the Apelin pathway activator, CMF-019, was applied to further verify the role of PDE3B on the Apelin pathway in CN-treated cells. Results CN restricted tumorigenesis of colon cancer in vivo. A total of 6 cuproptosis-related DEGs were discovered containing decreased 4 genes and elevated 2 genes in tissues from tumor mice with or without high dose CN treatment. PDE3B deficiency exerted intensified inhibitory effects of CN treatment on proliferative, migratory, and invasive capability, as well as further facilitated cuproptosis. Moreover, PDE3B deletion enhanced the suppression of CN in delaying tumorigenesis. Additionally, CN retarded the malignant phenotypes and contributed to the initiation of cuproptosis in cells via the PDE3B-mediated Apelin pathway. Conclusion Our study revealed CN delayed colon cancer by regulating PDE3B via suppression of the Apelin pathway, indicating the potential clinical relevance of CN in treating colon cancer. Highlights CN exerts anti-tumor effect in colon cancer. CN delays tumorigenesis through suppressing PDE3B. PDE3B silencing enhances cuproptosis in CN-treated cells. CN attenuates colon cancer by modulating PDE3B through via the Apelin pathway.
AbstractList Colon cancer, a prevalent malignancy occurs in the gastrointestinal tract with annually increasing incidence and mortality, and Clinacanthus nutans (Burm.f.) Lindau (CN) possesses anticancer activity in a wide spectrum of tumors. This investigation aims at illuminating potential anti-cancer properties and related mechanisms of CN against colon cancer.BACKGROUNDColon cancer, a prevalent malignancy occurs in the gastrointestinal tract with annually increasing incidence and mortality, and Clinacanthus nutans (Burm.f.) Lindau (CN) possesses anticancer activity in a wide spectrum of tumors. This investigation aims at illuminating potential anti-cancer properties and related mechanisms of CN against colon cancer.A BALB/c mice model of colon cancer administered CN to the experimental group was constructed, followed by transcriptome sequencing on tumor tissues and screening out cuproptosis-related differentially expressed genes (DEGs) through bioinformatics. The anti-tumor efficacy of CN was validated in HT29 and HCT116 cells co-treatment of CN and drug serum by functional assays and therapeutic effects on tumorigenicity were also evaluated in vivo. In addition, the impact of PDE3B silencing on cuproptosis was elucidated and the Apelin pathway activator, CMF-019, was applied to further verify the role of PDE3B on the Apelin pathway in CN-treated cells.METHODSA BALB/c mice model of colon cancer administered CN to the experimental group was constructed, followed by transcriptome sequencing on tumor tissues and screening out cuproptosis-related differentially expressed genes (DEGs) through bioinformatics. The anti-tumor efficacy of CN was validated in HT29 and HCT116 cells co-treatment of CN and drug serum by functional assays and therapeutic effects on tumorigenicity were also evaluated in vivo. In addition, the impact of PDE3B silencing on cuproptosis was elucidated and the Apelin pathway activator, CMF-019, was applied to further verify the role of PDE3B on the Apelin pathway in CN-treated cells.CN restricted tumorigenesis of colon cancer in vivo. A total of 6 cuproptosis-related DEGs were discovered containing decreased 4 genes and elevated 2 genes in tissues from tumor mice with or without high dose CN treatment. PDE3B deficiency exerted intensified inhibitory effects of CN treatment on proliferative, migratory, and invasive capability, as well as further facilitated cuproptosis. Moreover, PDE3B deletion enhanced the suppression of CN in delaying tumorigenesis. Additionally, CN retarded the malignant phenotypes and contributed to the initiation of cuproptosis in cells via the PDE3B-mediated Apelin pathway.RESULTSCN restricted tumorigenesis of colon cancer in vivo. A total of 6 cuproptosis-related DEGs were discovered containing decreased 4 genes and elevated 2 genes in tissues from tumor mice with or without high dose CN treatment. PDE3B deficiency exerted intensified inhibitory effects of CN treatment on proliferative, migratory, and invasive capability, as well as further facilitated cuproptosis. Moreover, PDE3B deletion enhanced the suppression of CN in delaying tumorigenesis. Additionally, CN retarded the malignant phenotypes and contributed to the initiation of cuproptosis in cells via the PDE3B-mediated Apelin pathway.Our study revealed CN delayed colon cancer by regulating PDE3B via suppression of the Apelin pathway, indicating the potential clinical relevance of CN in treating colon cancer.CONCLUSIONOur study revealed CN delayed colon cancer by regulating PDE3B via suppression of the Apelin pathway, indicating the potential clinical relevance of CN in treating colon cancer.
Colon cancer, a prevalent malignancy occurs in the gastrointestinal tract with annually increasing incidence and mortality, and Clinacanthus nutans (Burm.f.) Lindau (CN) possesses anticancer activity in a wide spectrum of tumors. This investigation aims at illuminating potential anti-cancer properties and related mechanisms of CN against colon cancer. A BALB/c mice model of colon cancer administered CN to the experimental group was constructed, followed by transcriptome sequencing on tumor tissues and screening out cuproptosis-related differentially expressed genes (DEGs) through bioinformatics. The anti-tumor efficacy of CN was validated in HT29 and HCT116 cells co-treatment of CN and drug serum by functional assays and therapeutic effects on tumorigenicity were also evaluated in vivo. In addition, the impact of PDE3B silencing on cuproptosis was elucidated and the Apelin pathway activator, CMF-019, was applied to further verify the role of PDE3B on the Apelin pathway in CN-treated cells. CN restricted tumorigenesis of colon cancer in vivo. A total of 6 cuproptosis-related DEGs were discovered containing decreased 4 genes and elevated 2 genes in tissues from tumor mice with or without high dose CN treatment. PDE3B deficiency exerted intensified inhibitory effects of CN treatment on proliferative, migratory, and invasive capability, as well as further facilitated cuproptosis. Moreover, PDE3B deletion enhanced the suppression of CN in delaying tumorigenesis. Additionally, CN retarded the malignant phenotypes and contributed to the initiation of cuproptosis in cells via the PDE3B-mediated Apelin pathway. Our study revealed CN delayed colon cancer by regulating PDE3B via suppression of the Apelin pathway, indicating the potential clinical relevance of CN in treating colon cancer.
CN exerts anti-tumor effect in colon cancer. CN delays tumorigenesis through suppressing PDE3B. PDE3B silencing enhances cuproptosis in CN-treated cells. CN attenuates colon cancer by modulating PDE3B through via the Apelin pathway.
Abstract Background Colon cancer, a prevalent malignancy occurs in the gastrointestinal tract with annually increasing incidence and mortality, and Clinacanthus nutans (Burm.f.) Lindau (CN) possesses anticancer activity in a wide spectrum of tumors. This investigation aims at illuminating potential anti-cancer properties and related mechanisms of CN against colon cancer. Methods A BALB/c mice model of colon cancer administered CN to the experimental group was constructed, followed by transcriptome sequencing on tumor tissues and screening out cuproptosis-related differentially expressed genes (DEGs) through bioinformatics. The anti-tumor efficacy of CN was validated in HT29 and HCT116 cells co-treatment of CN and drug serum by functional assays and therapeutic effects on tumorigenicity were also evaluated in vivo. In addition, the impact of PDE3B silencing on cuproptosis was elucidated and the Apelin pathway activator, CMF-019, was applied to further verify the role of PDE3B on the Apelin pathway in CN-treated cells. Results CN restricted tumorigenesis of colon cancer in vivo. A total of 6 cuproptosis-related DEGs were discovered containing decreased 4 genes and elevated 2 genes in tissues from tumor mice with or without high dose CN treatment. PDE3B deficiency exerted intensified inhibitory effects of CN treatment on proliferative, migratory, and invasive capability, as well as further facilitated cuproptosis. Moreover, PDE3B deletion enhanced the suppression of CN in delaying tumorigenesis. Additionally, CN retarded the malignant phenotypes and contributed to the initiation of cuproptosis in cells via the PDE3B-mediated Apelin pathway. Conclusion Our study revealed CN delayed colon cancer by regulating PDE3B via suppression of the Apelin pathway, indicating the potential clinical relevance of CN in treating colon cancer.
BackgroundColon cancer, a prevalent malignancy occurs in the gastrointestinal tract with annually increasing incidence and mortality, and Clinacanthus nutans (Burm.f.) Lindau (CN) possesses anticancer activity in a wide spectrum of tumors. This investigation aims at illuminating potential anti-cancer properties and related mechanisms of CN against colon cancer.MethodsA BALB/c mice model of colon cancer administered CN to the experimental group was constructed, followed by transcriptome sequencing on tumor tissues and screening out cuproptosis-related differentially expressed genes (DEGs) through bioinformatics. The anti-tumor efficacy of CN was validated in HT29 and HCT116 cells co-treatment of CN and drug serum by functional assays and therapeutic effects on tumorigenicity were also evaluated in vivo. In addition, the impact of PDE3B silencing on cuproptosis was elucidated and the Apelin pathway activator, CMF-019, was applied to further verify the role of PDE3B on the Apelin pathway in CN-treated cells.ResultsCN restricted tumorigenesis of colon cancer in vivo. A total of 6 cuproptosis-related DEGs were discovered containing decreased 4 genes and elevated 2 genes in tissues from tumor mice with or without high dose CN treatment. PDE3B deficiency exerted intensified inhibitory effects of CN treatment on proliferative, migratory, and invasive capability, as well as further facilitated cuproptosis. Moreover, PDE3B deletion enhanced the suppression of CN in delaying tumorigenesis. Additionally, CN retarded the malignant phenotypes and contributed to the initiation of cuproptosis in cells via the PDE3B-mediated Apelin pathway.ConclusionOur study revealed CN delayed colon cancer by regulating PDE3B via suppression of the Apelin pathway, indicating the potential clinical relevance of CN in treating colon cancer.HighlightsCN exerts anti-tumor effect in colon cancer.CN delays tumorigenesis through suppressing PDE3B.PDE3B silencing enhances cuproptosis in CN-treated cells.CN attenuates colon cancer by modulating PDE3B through via the Apelin pathway.
Background Colon cancer, a prevalent malignancy occurs in the gastrointestinal tract with annually increasing incidence and mortality, and Clinacanthus nutans (Burm.f.) Lindau (CN) possesses anticancer activity in a wide spectrum of tumors. This investigation aims at illuminating potential anti-cancer properties and related mechanisms of CN against colon cancer. Methods A BALB/c mice model of colon cancer administered CN to the experimental group was constructed, followed by transcriptome sequencing on tumor tissues and screening out cuproptosis-related differentially expressed genes (DEGs) through bioinformatics. The anti-tumor efficacy of CN was validated in HT29 and HCT116 cells co-treatment of CN and drug serum by functional assays and therapeutic effects on tumorigenicity were also evaluated in vivo. In addition, the impact of PDE3B silencing on cuproptosis was elucidated and the Apelin pathway activator, CMF-019, was applied to further verify the role of PDE3B on the Apelin pathway in CN-treated cells. Results CN restricted tumorigenesis of colon cancer in vivo. A total of 6 cuproptosis-related DEGs were discovered containing decreased 4 genes and elevated 2 genes in tissues from tumor mice with or without high dose CN treatment. PDE3B deficiency exerted intensified inhibitory effects of CN treatment on proliferative, migratory, and invasive capability, as well as further facilitated cuproptosis. Moreover, PDE3B deletion enhanced the suppression of CN in delaying tumorigenesis. Additionally, CN retarded the malignant phenotypes and contributed to the initiation of cuproptosis in cells via the PDE3B-mediated Apelin pathway. Conclusion Our study revealed CN delayed colon cancer by regulating PDE3B via suppression of the Apelin pathway, indicating the potential clinical relevance of CN in treating colon cancer. Highlights CN exerts anti-tumor effect in colon cancer. CN delays tumorigenesis through suppressing PDE3B. PDE3B silencing enhances cuproptosis in CN-treated cells. CN attenuates colon cancer by modulating PDE3B through via the Apelin pathway.
ArticleNumber 1521
Author Lin, Xueying
Chen, Xuewu
Zhou, Gaoyun
Su, Dewen
Lai, Zhiheng
Lin, Long
Author_xml – sequence: 1
  givenname: Gaoyun
  surname: Zhou
  fullname: Zhou, Gaoyun
  organization: Department of Surgery I, Guangdong Hospital of Traditional Chinese Medicine Hainan Hospital
– sequence: 2
  givenname: Xueying
  surname: Lin
  fullname: Lin, Xueying
  organization: Department of Oncology Intervention, Guangdong Hospital of Traditional Chinese Medicine Hainan Hospital
– sequence: 3
  givenname: Zhiheng
  surname: Lai
  fullname: Lai, Zhiheng
  organization: Department of Proctology, Guangdong Hospital of Traditional Chinese Medicine Hainan Hospital
– sequence: 4
  givenname: Dewen
  surname: Su
  fullname: Su, Dewen
  organization: Department of Surgery I, Guangdong Hospital of Traditional Chinese Medicine Hainan Hospital
– sequence: 5
  givenname: Long
  surname: Lin
  fullname: Lin, Long
  email: 13907629038@163.com
  organization: Department of Surgery I, Guangdong Hospital of Traditional Chinese Medicine Hainan Hospital
– sequence: 6
  givenname: Xuewu
  surname: Chen
  fullname: Chen, Xuewu
  email: dahei_858812@163.com
  organization: Department of Oncology Intervention, Guangdong Hospital of Traditional Chinese Medicine Hainan Hospital
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40788438$$D View this record in MEDLINE/PubMed
BookMark eNp9ks1u1DAQgCNUREvpC3BAlriUQxY7dhL7hNqlQKWV4ABna9Y_Wa-ydrATVvsYvDFmU0rLgYNly_PN55-Z58WJD94UxUuCFwTj9m0iVdNWJa7qPDBty_2T4qxqKS4bTMjJg_VpcZHSFuOMEkpx_aw4ZbjlnFF-Vvxc9s6DAj9upoT8NIJP6PJ6iruFXbxBK-c1TMiCcr0bYTQJqWmIYRhDcgmB1wh2pnchzrHQB4-yTZmIMtZFk5LLW-sDcn7j1m50vkNf3t_Q63JntMtZGl0N2eDRAONmD4cXxVMLfTIXd_N58e3Dzdflp3L1-ePt8mpVKobFvtTaCA2a1LjmTDBe25rA2jLMG1xR0bbYNlwJYRstMFWCGhC8YtQKY1uwLT0vbmevDrCVQ3Q7iAcZwMnjRoidhDg61RvJoeUKsgETzgjRorYNazjjhGBLlc6ud7NrmNb5Wcr4MUL_SPo44t1GduGHJBWlgtMmGy7vDDF8n0wa5c4lZfoevAlTkrSiuWBVw2hGX_-DbsMUff6rI1VXosYsU68eXun-Ln9Kn4FqBlQMKUVj7xGC5e8Wk3OLydw38thicp-T6JyUMuw7E_-e_Z-sXxc71PU
Cites_doi 10.1038/s41598-018-32267-8
10.1093/abbs/gmab134
10.1186/s12951-024-02480-x
10.1158/1541-7786.MCR-18-0989
10.1002/tox.22629
10.1158/1541-7786.MCR-20-0991
10.1007/s12079-023-00779-2
10.1007/s00268-021-06188-z
10.1016/j.intimp.2017.01.013
10.3748/wjg.v29.i4.670
10.1038/s41434-020-0167-3
10.1016/j.prp.2020.153247
10.3390/cimb45100536
10.1007/s00210-023-02928-1
10.21873/anticanres.14760
10.1016/j.carbpol.2015.10.102
10.1158/1078-0432.CCR-18-0815
10.2174/0115665232273077240104045022
10.3390/ijms241310789
10.3390/ijms231810600
10.1016/j.ejphar.2021.174464
10.7555/JBR.34.20200021
10.1186/s12906-019-2663-9
10.1007/s11356-022-20858-y
10.1080/13880209.2017.1288749
10.1002/ptr.7521
10.1080/01635581.2021.2014901
10.3389/fphar.2024.1290592
10.1371/journal.pone.0256012
10.1016/j.jnutbio.2024.109623
10.1002/jbt.23525
10.1177/00368504211011341
ContentType Journal Article
Copyright The Author(s) 2025
2025. The Author(s).
The Author(s) 2025. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2025 2025
Copyright_xml – notice: The Author(s) 2025
– notice: 2025. The Author(s).
– notice: The Author(s) 2025. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2025 2025
DBID C6C
AAYXX
CITATION
NPM
3V.
7RV
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
KB0
M0S
NAPCQ
PHGZM
PHGZT
PIMPY
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
7X8
5PM
DOA
DOI 10.1007/s12672-025-02037-w
DatabaseName Springer Nature OA Free Journals
CrossRef
PubMed
ProQuest Central (Corporate)
Nursing & Allied Health Database
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
ProQuest Health & Medical Collection
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Central
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
PubMed


Publicly Available Content Database

Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2730-6011
EndPage 15
ExternalDocumentID oai_doaj_org_article_8a78ca3ea018411d95f646848110f3cd
PMC12339836
40788438
10_1007_s12672_025_02037_w
Genre Journal Article
GeographicLocations Beijing China
United States--US
China
Shenzhen China
Shanghai China
GeographicLocations_xml – name: Shenzhen China
– name: China
– name: Shanghai China
– name: Beijing China
– name: United States--US
GroupedDBID 0R~
2JY
53G
7RV
7X7
8FI
8FJ
AAJSJ
AASML
ABUWG
AFBBN
AFKRA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
BENPR
C6C
CCPQU
EBS
FYUFA
GROUPED_DOAJ
HMCUK
NAPCQ
PGMZT
PHGZM
PHGZT
PIMPY
PPXIY
RPM
SOJ
UKHRP
AAYXX
CITATION
NPM
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQQKQ
PQUKI
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c409w-dde9dad1505849485f51abf40860239770f68c99f6d903c93ea98243f9ef7af73
IEDL.DBID DOA
ISSN 2730-6011
IngestDate Wed Aug 27 01:31:51 EDT 2025
Thu Aug 21 18:28:13 EDT 2025
Mon Aug 11 17:31:14 EDT 2025
Sat Aug 23 12:22:00 EDT 2025
Fri Aug 15 02:01:21 EDT 2025
Thu Aug 21 00:12:33 EDT 2025
Tue Aug 12 01:10:43 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Apelin pathway
(Burm.f.) Lindau
Colon cancer
Cuproptosis
PDE3B
Clinacanthus nutans (Burm.f.) Lindau
Language English
License 2025. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c409w-dde9dad1505849485f51abf40860239770f68c99f6d903c93ea98243f9ef7af73
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://doaj.org/article/8a78ca3ea018411d95f646848110f3cd
PMID 40788438
PQID 3238529504
PQPubID 5642930
PageCount 15
ParticipantIDs doaj_primary_oai_doaj_org_article_8a78ca3ea018411d95f646848110f3cd
pubmedcentral_primary_oai_pubmedcentral_nih_gov_12339836
proquest_miscellaneous_3238432643
proquest_journals_3238529504
pubmed_primary_40788438
crossref_primary_10_1007_s12672_025_02037_w
springer_journals_10_1007_s12672_025_02037_w
PublicationCentury 2000
PublicationDate 20250811
PublicationDateYYYYMMDD 2025-08-11
PublicationDate_xml – month: 8
  year: 2025
  text: 20250811
  day: 11
PublicationDecade 2020
PublicationPlace New York
PublicationPlace_xml – name: New York
– name: United States
PublicationTitle Discover. Oncology
PublicationTitleAbbrev Discov Onc
PublicationTitleAlternate Discov Oncol
PublicationYear 2025
Publisher Springer US
Springer Nature B.V
Springer
Publisher_xml – name: Springer US
– name: Springer Nature B.V
– name: Springer
References IN Zulkipli (2037_CR40) 2017; 55
KM Abdullah (2037_CR13) 2024; 10
Z Sun (2037_CR28) 2020; 35
M Rahimpour (2037_CR21) 2022; 74
Y Feng (2037_CR34) 2024
FJ Nordin (2037_CR10) 2021; 16
OP Pulkka (2037_CR19) 2019; 25
NZ Ismail (2037_CR27) 2022; 29
L Wei (2037_CR30) 2022; 29
Y Ruan (2037_CR14) 2024; 13
CM Lin (2037_CR7) 2023; 24
Q Feng (2037_CR12) 2024; 15
D Neelakantan (2037_CR37) 2019; 17
V Karpisheh (2037_CR23) 2020; 216
SN Jia (2037_CR1) 2022; 86
T Liu (2037_CR18) 2023; 45
S Sriramulu (2037_CR22) 2024; 24
M Li (2037_CR32) 2022; 36
S Wahab (2037_CR3) 2021; 910
M PodgOrska (2037_CR20) 2021; 41
MC Lu (2037_CR26) 2018; 33
D Huang (2037_CR9) 2016; 137
S Dogra (2037_CR36) 2021; 19
CF Le (2037_CR6) 2017; 44
A Dey (2037_CR24) 2023; 22
LW Hii (2037_CR11) 2019; 19
P Ravindranathan (2037_CR33) 2018; 8
X Wang (2037_CR15) 2023; 13
Y Feng (2037_CR31) 2024; 129
N Pavlaki (2037_CR17) 2018; 5
YC He (2037_CR5) 2023; 29
C Chaves-Almagro (2037_CR38) 2022; 23
Q Tian (2037_CR39) 2021; 53
RFW Franssen (2037_CR4) 2021; 45
Y Chen (2037_CR35) 2021; 104
LK Boopathy (2037_CR2) 2024; 38
CM Lin (2037_CR8) 2021; 2021
YK Yong (2037_CR25) 2013; 2013
L Qiao (2037_CR16) 2024; 22
G Khalili-Tanha (2037_CR29) 2023; 17
References_xml – volume: 8
  start-page: 13869
  issue: 1
  year: 2018
  ident: 2037_CR33
  publication-title: Sci Rep
  doi: 10.1038/s41598-018-32267-8
– volume: 53
  start-page: 1538
  issue: 11
  year: 2021
  ident: 2037_CR39
  publication-title: Acta Biochim Biophys Sin
  doi: 10.1093/abbs/gmab134
– volume: 22
  start-page: 205
  issue: 1
  year: 2024
  ident: 2037_CR16
  publication-title: J Nanobiotechnol
  doi: 10.1186/s12951-024-02480-x
– volume: 17
  start-page: 1378
  issue: 6
  year: 2019
  ident: 2037_CR37
  publication-title: Mol Cancer Res
  doi: 10.1158/1541-7786.MCR-18-0989
– volume: 33
  start-page: 1229
  issue: 12
  year: 2018
  ident: 2037_CR26
  publication-title: Environ Toxicol
  doi: 10.1002/tox.22629
– volume: 19
  start-page: 1534
  issue: 9
  year: 2021
  ident: 2037_CR36
  publication-title: Mol Cancer Res
  doi: 10.1158/1541-7786.MCR-20-0991
– volume: 17
  start-page: 1469
  issue: 4
  year: 2023
  ident: 2037_CR29
  publication-title: J Cell Commun Signal
  doi: 10.1007/s12079-023-00779-2
– volume: 45
  start-page: 2924
  issue: 9
  year: 2021
  ident: 2037_CR4
  publication-title: World J Surg
  doi: 10.1007/s00268-021-06188-z
– volume: 44
  start-page: 203
  year: 2017
  ident: 2037_CR6
  publication-title: Int Immunopharmacol
  doi: 10.1016/j.intimp.2017.01.013
– volume: 10
  issue: 5
  year: 2024
  ident: 2037_CR13
  publication-title: Heliyon
– volume: 29
  start-page: 670
  issue: 4
  year: 2023
  ident: 2037_CR5
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v29.i4.670
– volume: 29
  start-page: 28
  issue: 1–2
  year: 2022
  ident: 2037_CR30
  publication-title: Gene Ther
  doi: 10.1038/s41434-020-0167-3
– volume: 13
  issue: 4
  year: 2024
  ident: 2037_CR14
  publication-title: Adv Healthc Mater
– volume: 216
  issue: 12
  year: 2020
  ident: 2037_CR23
  publication-title: Pathol Res Pract
  doi: 10.1016/j.prp.2020.153247
– volume: 86
  start-page: 400
  issue: Pt 3
  year: 2022
  ident: 2037_CR1
  publication-title: Semin Cancer Biol
– volume: 45
  start-page: 8502
  issue: 10
  year: 2023
  ident: 2037_CR18
  publication-title: Curr Issues Mol Biol
  doi: 10.3390/cimb45100536
– volume: 22
  start-page: 153303382311784
  year: 2023
  ident: 2037_CR24
  publication-title: Technol Cancer Res Treat
– year: 2024
  ident: 2037_CR34
  publication-title: Naunyn Schmiedebergs Arch Pharmacol
  doi: 10.1007/s00210-023-02928-1
– volume: 41
  start-page: 151
  issue: 1
  year: 2021
  ident: 2037_CR20
  publication-title: Anticancer Res
  doi: 10.21873/anticanres.14760
– volume: 5
  start-page: 4
  issue: 1
  year: 2018
  ident: 2037_CR17
  publication-title: J Cardiovasc Dev Dis
– volume: 137
  start-page: 701
  year: 2016
  ident: 2037_CR9
  publication-title: Carbohydr Polym
  doi: 10.1016/j.carbpol.2015.10.102
– volume: 13
  year: 2023
  ident: 2037_CR15
  publication-title: Front Oncol
– volume: 25
  start-page: 1676
  issue: 5
  year: 2019
  ident: 2037_CR19
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-18-0815
– volume: 24
  start-page: 307
  issue: 4
  year: 2024
  ident: 2037_CR22
  publication-title: Curr Gene Ther
  doi: 10.2174/0115665232273077240104045022
– volume: 24
  start-page: 10789
  issue: 13
  year: 2023
  ident: 2037_CR7
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms241310789
– volume: 2021
  start-page: 5560502
  year: 2021
  ident: 2037_CR8
  publication-title: Evid Based Complement Alternat Med
– volume: 23
  start-page: 10600
  issue: 18
  year: 2022
  ident: 2037_CR38
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms231810600
– volume: 910
  year: 2021
  ident: 2037_CR3
  publication-title: Eur J Pharmacol
  doi: 10.1016/j.ejphar.2021.174464
– volume: 35
  start-page: 21
  issue: 1
  year: 2020
  ident: 2037_CR28
  publication-title: J Biomed Res
  doi: 10.7555/JBR.34.20200021
– volume: 19
  start-page: 257
  issue: 1
  year: 2019
  ident: 2037_CR11
  publication-title: BMC Complement Altern Med
  doi: 10.1186/s12906-019-2663-9
– volume: 29
  start-page: 81685
  issue: 54
  year: 2022
  ident: 2037_CR27
  publication-title: Environ Sci Pollut Res Int
  doi: 10.1007/s11356-022-20858-y
– volume: 55
  start-page: 1093
  issue: 1
  year: 2017
  ident: 2037_CR40
  publication-title: Pharm Biol
  doi: 10.1080/13880209.2017.1288749
– volume: 36
  start-page: 3540
  issue: 9
  year: 2022
  ident: 2037_CR32
  publication-title: Phytother Res
  doi: 10.1002/ptr.7521
– volume: 74
  start-page: 2622
  issue: 7
  year: 2022
  ident: 2037_CR21
  publication-title: Nutr Cancer
  doi: 10.1080/01635581.2021.2014901
– volume: 15
  start-page: 1290592
  year: 2024
  ident: 2037_CR12
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2024.1290592
– volume: 16
  issue: 8
  year: 2021
  ident: 2037_CR10
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0256012
– volume: 129
  year: 2024
  ident: 2037_CR31
  publication-title: J Nutr Biochem
  doi: 10.1016/j.jnutbio.2024.109623
– volume: 38
  issue: 1
  year: 2024
  ident: 2037_CR2
  publication-title: J Biochem Mol Toxicol
  doi: 10.1002/jbt.23525
– volume: 2013
  year: 2013
  ident: 2037_CR25
  publication-title: Evid Based Complement Alternat Med
– volume: 104
  start-page: 368504211011341
  issue: 2
  year: 2021
  ident: 2037_CR35
  publication-title: Sci Prog
  doi: 10.1177/00368504211011341
SSID ssj0002513305
Score 2.299654
Snippet Background Colon cancer, a prevalent malignancy occurs in the gastrointestinal tract with annually increasing incidence and mortality, and Clinacanthus nutans...
Colon cancer, a prevalent malignancy occurs in the gastrointestinal tract with annually increasing incidence and mortality, and Clinacanthus nutans (Burm.f.)...
BackgroundColon cancer, a prevalent malignancy occurs in the gastrointestinal tract with annually increasing incidence and mortality, and Clinacanthus nutans...
CN exerts anti-tumor effect in colon cancer. CN delays tumorigenesis through suppressing PDE3B. PDE3B silencing enhances cuproptosis in CN-treated cells. CN...
Abstract Background Colon cancer, a prevalent malignancy occurs in the gastrointestinal tract with annually increasing incidence and mortality, and...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 1521
SubjectTerms Apelin pathway
Cancer Research
Cell death
Clinacanthus nutans (Burm.f.) Lindau
Colon cancer
Colorectal cancer
Copper
Cuproptosis
Gas flow
Internal Medicine
Medicine
Medicine & Public Health
Molecular Medicine
Oncology
PDE3B
Proteins
Radiotherapy
Software
Surgical Oncology
Tumors
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIgL4t1AqYzEAQQuSezE9gl1oVWFVMSBSnuLxk7MRmqTZbPRqj-Df4zHye5qy-Ma-zDxzNifPTPfEPJaSWMNeP-WsTNMuEwwpQywJAOZcgO5cVjgfP41P7sQX6bZdHxw68a0yvWeGDbqsrX4Rv6B-7MFg1Kx-Dj_ybBrFEZXxxYat8kdpC7DlC45lZs3lhSbl8TZWCszVMyluUwZ9nDFEJxkq53zKND2_w1r_pkyeSNuGo6j0wfk_ogj6fGg-IfkVtU8InfPx0j5Y_ILQ7OA6zbrO9r0HgN29M2kX1wduaO3NFzFe-rADizdVUdt7-WZL9uu7ig0JYWr6hLr98OY3yIbatFCFjSkdA10HtRc07qZ1abG7Gn67fMJn7BQjOKBLD2eY7E7xabHK7h-Qi5OT75_OmNj-wVm_aVvxfzGp0soPWL0IAVJZFyWgHEixrZViBtjlyurtctLHXOreQVapYI7XTkJTvKnZK9pm2qfUGkzraVOVAVGeEgCJsldDMpajzYyEBF5t1ZCMR9YNootnzKqrPAqK4LKilVEJqinzUxkyA4f2sWPYnS4QoFUFrxMsb_DJkmpM5eLHJsHJLHjtozIwVrLxei2XbE1soi82gx7h8MoCjRV2w9zhAe9gkfk2WAUG0kwKOoHVUTUjrnsiLo70tSzQOrtEQTXiucReb-2rK1c_16L5___jRfkXhqMXbEkOSB7y0VfvfQoamkOg6v8BnxjHLE
  priority: 102
  providerName: ProQuest
– databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Nb9QwELWgSIgL4pvQgozEAQQucew49rG7tKqQijhQqbfIdmJtJJpdbTZa9WfwjzvjZLfaUg5cY0caZWbs5zzPG0I-6MJ5ZyG_izQ4JkMumdbOMp7bIhPOKhewwPnshzo9l98v8otRJgdrYW7x9187nqkiY9h0FTmzgq3vkwc5FwojeKqm2_8pGTYqSfOxLubuV3f2nijRfxeu_Pt65C2ONG49J0_I4xEz0qPByU_Jvbp9Rh6ejaz4c_IHaViL32jWd7TtAe919OOkX14ehsNPNB67exqsHxS56476HuxZrOZd01HbVtRe1r-xVj-OwXLYUo_RsKTx-tYg3UHdFW3aWeMavClNf347FhMWC08AtNKjBRa2U2xwvLZXL8j5yfGv6SkbWy0wDwe8NYNFzlS2AnQIgAQFY0LOrQsyxRZViBHToLQ3JqjKpMIbUVujMymCqUNhQyFekr123tavCS18bkxhuK6tkwA_rOMqpFZ7D8gitzIhnzdOKBeDokZ5o52MLivBZWV0WblOyAT9tJ2JatjxAQRJOSZXqW2hvQWbUjivcl6ZPCipsFEAT4PwVUIONl4uxxTtSgFgBVnOFCx6vx2G5ELGxLb1vB_mSAC4UiTk1RAUW0uQAIVBnRC9Ey47pu6OtM0sCngDWhBGC5WQL5vIurHr39_izf9N3yePshj8mnF-QPZWy75-Cwhq5d7F1LkGXj8V_Q
  priority: 102
  providerName: Springer Nature
Title Clinacanthus nutans (Burm.f.) Lindau facilitates cuproptosis and ameliorates colon cancer progression by inhibiting PDE3B-mediated Apelin pathway
URI https://link.springer.com/article/10.1007/s12672-025-02037-w
https://www.ncbi.nlm.nih.gov/pubmed/40788438
https://www.proquest.com/docview/3238529504
https://www.proquest.com/docview/3238432643
https://pubmed.ncbi.nlm.nih.gov/PMC12339836
https://doaj.org/article/8a78ca3ea018411d95f646848110f3cd
Volume 16
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9tAEF7aFEovpe-qTc0WemhplUja1T6OsesQCgmhNOCb2F1psaGRjWVh8jPyjzOzkp24D3rpUVodhnnsfqPZ-YaQD0paZw3Et0y8jbnPeayUNXGaG5kxa4T12OB8eiZOLvi3ST65M-oL74R19MCd4g6VkcoZVpkEcpE0LXXuBRdIAp8mnrkSd1848-4kU7gHZzi2JMn7LpmuVy4TMotxeisW32S83jmJAmH_n1Dm75clf6mYhoPo-Al53CNIetRJ_pTcq-pn5OFpXyN_Tq6xKGtQY9O2oXUL6K-hH4ft8vLAH3yiIQlvqTeu4-euGupakGexmjezhpq6pOay-omd-2ENNseaOvSNJQ2XuToiD2qv6KyezuwM703T869jNoxDGwpAWHq0wDZ3iuOO1-bqBbk4Hv8YncT94IXYQbq3jmHL06UpASsCPEH6GJ-nxnqe4MAqRIyJF8pp7UWpE-Y0WEerjDOvKy-Nl-wl2avndfWaUOlyraVOVWUsBzBibCp8YpRzgDNywyPyeWOEYtHxaxS3TMposgJMVgSTFeuIDNFO2y-RGzu8AI8peo8p_uUxEdnfWLnoA7YpGEAXrHkmINH77TKEGtZPTF3N2-4bDnCXs4i86pxiKwmWQ2FRRUTtuMuOqLsr9Wwa6LwBOzCtmIjIl41n3cr1d128-R-6eEseZSEkVJym-2RvtWyrd4CyVnZA7suJHJAHw_HZ-Xd4GonRIATZIPwSuwEIiCj2
linkProvider Directory of Open Access Journals
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbtNAEF2VVAJeEHcMBRYJJBB1sb1re_cBoYamSmkTVaiV-mZ2114SiTohjhXlM_gRvpEZXxKF21tfs1Y0yZnZPePZmUPISxFroxXEd-xZ7XIbclcIrVw_VHHAtIq0xQbnwTDqn_NPF-HFFvnZ9sLgtcp2T6w26nRi8B35OwZnCxalPP5h-t1F1SisrrYSGrVbHGfLBaRsxfujA8D3VRAc9s4-9t1GVcA1kMssXIhnmaoUiBCcvTgbxYa-0pZ7qMaEdMizkTBS2iiVHjOSZUqKgDMrMxsrGzP43mtkmzNIZTpku9sbnn5evdUJUC7FC5vunLpHL4jiwEXVWCz6xe5i4wSshAL-xm7_vKT5W6W2OgAPb5NbDXOl-7Wr3SFbWX6XXB80tfl75AcWgxUiNSoLmpfAOgv6ulvOLvfs3htaJf8ltcrUc8GzgpoS7JnOJ8W4oCpPqbrMvuHEgGoNNuWcGvTJGa0ukdUDRKhe0nE-Gusx3tempwc91nWr9hegznR_iu31FGWWF2p5n5xfCTQPSCef5NkjQmMTShlLX2RKcyBBSvuR9ZQwBvhNqLhD3rYgJNN6rkeynuCMkCUAWVJBliwc0kWcVk_iTO7qg8nsa9KEeCJULIwCmzzImn0_laGNeIRyBb5nmUkdstOinDQbRZGs3dohL1bLEOJYt1F5NinrZzjQbM4c8rB2ipUlWIaFReEQseEuG6ZuruTjUTVGHDgLk4JFDtltPWtt17__i8f__xnPyY3-2eAkOTkaHj8hN4PK8YXr-zukM5-V2VPgcHP9rAkcSr5cdaz-AhDLWmA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGkCZeEHcCA4wEEgiyJXES2w8IrXTVxti0Byb1LdhOTCuxtDSNqv4M_g6_jnOcpFW5ve01tqKTfOfYn31uhLwQXButwL55YLUf2yT2hdDKDxPFI6ZVqi0mOJ-epUcX8cdhMtwiP7tcGAyr7NZEt1DnE4N35PsM9hZ0SgXxvm3DIs77g_fT7z52kEJPa9dOo1GRk2K5gONb9e64D1i_jKLB4ecPR37bYcA3cK5Z-GDbMlc5kCLYh7FOik1CpW0cYGcmpEaBTYWR0qa5DJiRrFBSRDGzsrBcWc7gvdfIdc6SEG2MD_nqfifCxilB0ubpNNl6UcojH_vHovuP-4uNvdC1DPgbz_0zXPM3n63bCge3yM2Ww9KDRuluk62ivEN2Tlsv_V3yA93CCjEb1RUta-CfFX3Vq2eXe3bvNXXXADW1yjQVwouKmhrkmc4n1biiqsypuiy-Ye0ANwbLc0kNaueMunCyppQI1Us6LkdjPcbIbXreP2Q93yXCAImmB1NMtKfYcHmhlvfIxZUAc59sl5OyeEgoN4mUXIaiUDoGOqR0mNpACWOA6SQq9sibDoRs2lT4yNa1nBGyDCDLHGTZwiM9xGk1E6tzuweT2desNfZMKC6MApkCOD-HYS4Tm8YpNi4IA8tM7pHdDuWsXTKqbK3gHnm-GgZjRw-OKotJ3cyJgXDHzCMPGqVYSYIOWRgUHhEb6rIh6uZIOR65guLAXpgULPXI206z1nL9-188-v9nPCM7YKHZp-Ozk8fkRuT0XvhhuEu257O6eAJkbq6fOquh5MtVm-kvTGVdMA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinacanthus+nutans+%28Burm.f.%29+Lindau+facilitates+cuproptosis+and+ameliorates+colon+cancer+progression+by+inhibiting+PDE3B-mediated+Apelin+pathway&rft.jtitle=Discover.+Oncology&rft.au=Gaoyun+Zhou&rft.au=Xueying+Lin&rft.au=Zhiheng+Lai&rft.au=Dewen+Su&rft.date=2025-08-11&rft.pub=Springer&rft.eissn=2730-6011&rft.volume=16&rft.issue=1&rft.spage=1&rft.epage=15&rft_id=info:doi/10.1007%2Fs12672-025-02037-w&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_8a78ca3ea018411d95f646848110f3cd
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2730-6011&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2730-6011&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2730-6011&client=summon